Johnson & Johnson has named Tom Cavanaugh as the next leader of its innovative medicines business, beginning Sept. 1, 2026.
Jennifer Taubert, 62, the current worldwide chair of J&J Innovative Medicine, will retire after more than 21 years at the company, J&J announced Tuesday.
Taubert joined J&J’s executive committee in 2018 when she was elevated from leading the pharmaceuticals unit’s operations in the Americas to heading up the entire department, just as her predecessor Joaquin Duato moved up to become then-CEO Alex Gorsky’s right hand. She was named one of the Fiercest Women in Life Sciences in 2019.
Taubert naturally adopted her current title when the Big Pharma rebranded Janssen into J&J Innovative Medicine in September 2023.
Under Taubert’s leadership, J&J’s drugs business saw revenues swell from $40.7 billion for full-year 2018 to $31.8 billion for the first half of 2026 alone.
“Jennifer has made an extraordinary impact on patients, our business, and generations of leaders across our Company,” Duato, now chairman and CEO of J&J, said in an Aug. 4 statement. “Her vision, leadership, unwavering commitment to healthcare innovation, and passion for talent development helped define an era of growth and position us for future success.”
Cavanaugh, a 15-year Celgene veteran, joined J&J in 2017, initially as president of U.S. oncology and later as president of U.S. immunology before moving to chair the innovative medicine department’s North America business last year.
“I am confident his deep understanding of our business, proven track record of growth, and focus on developing people will ensure we are poised to continue to deliver for patients, healthcare systems, and our company,” Duato said of Cavanaugh in a statement. READ MORE
By Angus Liu
Source: fiercepharma.com
BioNTech has named the head of Swedish pharmaceutical company Sobi to be its next CEO, marking the latest step of a transformation that will see the prominent messenger RNA drugmaker become more of an oncology specialist.
I am one of thousands of clients who has had something flagged as a potential issue, then later found no further treatment was required. Some doctors say this causes unnecessary anxiety and that patients should only rely on national screening programmes.
Argenx will pay $77 a share in cash, valuing the U.S. drug developer at about $2.2 billion, in a deal that gives it a first-in-class anti-CD122 antibody that has shown early promise in vitiligo and celiac disease.
